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Background: X-linked lymphoproliferative disease type 1 (XLP1) belongs to genetically determined primary immunodeficiency syn-
dromes with mutations in SH2D1A/DSHP/SAP gene. The dramatic increase of the risk of B-cell lymphoma development in XLP1 pa-
tients is linked not only to SAP deficiency of NK, NKT and T cells, but probably to the impairment of B cell differentiation. Aim: To an-
alyze the receptor-mediated Akt/PKB and ERK1/2 phosphorylation and expression of transcription factors that are involved in B cell 
maturation in EBV-transformed B-lymphoblastoid cell lines (B-LCLs) from XLP1 patients (XLP B-LCLs) in comparison with 
conventional B-LCLs. Methods: Studies were performed on EBV-transformed XLP B-LCLs IARC 739, SC-XLP and RP-XLP 
in comparison with SAP-negative B-LCL T5-1 and SAP-positive B-LCL MP-1. Western blot analysis was used for evaluation of Akt 
(Ser473) and ERK1/2 (Thr202/Tyr204) phosphorylation in response to ligation of CD150, CD40, and IgM cell surface receptors. 
The expression levels of transcription factors IRF4, IRF8, BCL6, BLIMP1, SPIB, PU.1 and MITF were assessed using quantita-
tive RT-PCR. Results: It was shown that SAP deficiency in XLP B-LCL did not abrogate CD150-mediated Akt and ERK1/2 phos-
phorylation. At the same time, ligation of CD150 or IgM affects kinetics and amplitude of ERK1/2 activation. In XLP B-LCL 
the CD150 signaling with IgM coligation play the dominant role in both Akt and ERK1/2 phosphorylation. We found that signifi-
cantly reduced IRF4, IRF8 and PU.1 expression levels are the key features of XLP B-LCLs. Conclusion: XLP B-LCLs and conven-
tional B-LCLs have differences in kinetics and amplitude of Akt and ERK1/2 phosphorylation. Analysis of transcription factors 
profile revealed the distinguishing features of XLP B-LCLs with SAP deficiency that may impair B cell differentiation.
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X-linked lymphoproliferative disease type 1 (XLP1) 
belongs to X-linked genetically determined primary 
immunodeficiency syndromes and is characterized 
by mutations in SH2D1A/DSHP/SAP gene [1–3]. 
SH2D1A gene encodes a small 128 aa adaptor pro-
tein SH2 domain protein 1A (SH2D1A), also called 
Duncan’s disease SH2-protein (DSHP) or SLAM-
associated protein (SAP) [4–6]. SAP was first identi-
fied as an adaptor protein interacting with signaling 
lymphocyte activation molecule (SLAM)/CD150 [6]. 
This SH2 domain-containing adaptor protein inte-
racts with six members of SLAM family receptors 
by binding to conserved immunoreceptor tyrosine-
based switch motif (ITSM) and recruiting Src-family 
kinases [2, 7–9]. It was shown that SAP is involved 
in regulation of development and functions of T lym-
phocytes, NKT and NK cells [10–14]. XLP is characte-
rized by extreme vulnerability to Epstein – Barr virus 
(EBV) infection. Symptoms of EBV infection are typi-
cally mild and often indistinguishable from other mild 
common illnesses [15]. During primary infection, EBV 
infects and activates resting naive B-cells, which then 
transit through the germinal center to become resting 
memory B-cells where the virus resides quiescently. 
The ability of EBV to restrict expression of its genes 
allows the virus to persist in vivo within resting memory 
B cells and maintain a lifelong infection. Elimination 
of EBV-infected proliferating B cells is under control 
of cytotoxic T lymphocytes, NK and NKT cells [16, 17]. 
XLP1 patients have increased susceptibility to primary 
EBV infection and developed a fulminant form of infec-
tious mononucleosis with high rate of mortality. Other 
clinical characteristics are: uncontrolled proliferation 
of EBV infected B cells, lack of class-switched memory 
B cells, development of dysgammaglobulinaemia and 
lymphoma of B cell origin [1, 18–21]. Results of SAP-
deficiency studies suggested that defects in deve-
lopment and/or functions of CD8+ T lymphocytes, 
NK, and NKT cells are responsible for failure of EBV-
infected B cells elimination [2, 3, 22]. However, several 
XLP1 clinical features, inclu ding lymphoma develop-
ment, in many cases are EBV independent [23–25]. 
It should be noted that the risk for B-cell lymphoma de-
velopment in XLP1 patients is increased 200-fold [26]. 
A number of evidence [8, 27–33] support the idea that 
SAP is involved in B cell differentiation and function, 
so the absence of functional SAP in XLP1 may affect 
the B cells as well. Our previous publication present 
the proofs of intrinsic defect in B-lymphoblastoid 
cell lines (B-LCLs) derived from XLP1 patients [34]. 
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We used the EBV-transformed B-LCLs as an important 
model for studying cellular transformation, especially 
B-LCLs from XLP1 patients. Our studies revealed cell 
surface phenotype and functional features that 
distinguish XLP B-LCLs from conventional B-LCLs. 
The major functional differences are in the modulation 
of CD95 apoptosis via CD40 and CD150 receptors 
and unresponsiveness to proliferative signals trig-
gered by CD40 or coligation BCR with CD150 in XLP 
B-LCLs [34]. Current study covers some cell sig naling 
events that may underlie functional peculiarities 
of XLP B-LCLs, and transcription factors expression 
profile of XLP B-LCLs in comparison with conventional 
 B-LCLs. Since CD150 is a major SAP interacting recep-
tor and is linked to Akt/PKB and ERK1/2 pathways 
[27, 28], here we focused on receptor-mediated Akt/
PKB and ERK1/2 phosphorylation. SAP deficiency 
could also affect B-cell maturation. That is why, ex-
pression studies embrace seven transcription factors 
that are involved in B lymphocytes differentiation.
MATERIALS AND METHODS
Cell lines and stimulation. Studies were per-
formed on EBV-transformed B-LCL T5-1 (SAP-ne-
gative on protein level); SAP-positive B-LCL MP-1 (pro-
vided by Prof. E.A. Clark, USA); and EBV-transformed 
B-LCLs from XLP1 patients: IARC 739 (interstitial 
deletion of SH2D1A) [4], SC-XLP (S28R) [35], and 
RP-XLP (R55X), all kindly provided by Prof. K.E. Ni-
chols (USA). Cell lines were maintained as previously 
described [29]. For crosslinking of surface recep-
tors, we used the following monoclonal antibodies 
(mAbs): IPO-3 anti-CD150 (IgG1) (IEPOR NANU) and 
G28-5 anti-CD40 (IgG1) (kind gift of Prof. E.A. Clark, 
USA). F(ab)’2 of goat anti-human IgM (Jackson Im-
munoResearch Laboratories, Inc., USA) were used for 
IgM crosslinking on human B cell lines. Following final 
concentrations of antibodies were used: 0.5 μg/ml an-
ti-CD40, 1.0 μg/ml anti-CD95, 10.0 μg/ml anti-CD150, 
and 10.0 μg/ml anti-IgM.
Biochemical methods. Cell stimulation via cell 
surface receptors were stopped by cold PBS with 
0.1% NaN3, washed with the same solution, and cell 
pellets were lysed in Triton lysis buffer (150 mM NaCl, 
1 mM EDTA, 1 mM EGTA, 20 mM Tris, pH 8.0, 1% Triton 
Х100) containing cocktails of protease and phospha-
tase inhibitors (Sigma, USA). Lysates were subjected 
to sodium dodecyl sulfate polyacrylamide gel elec-
trophoresis. Proteins were transferred to Immobilon-
NC membranes (Millipore, USA) and blocked overnight 
with 5% nonfat dried milk in tris-buffered saline with 
tween 20 (TBS-T). Membranes were incubated with 
primary antisera at 4 °C for 12 h and with secondary 
antibodies for 2 h. Primary antibodies, rabbit anti-pAkt 
(Ser473) and anti-phosphorylated ERK1/2 (Thr202/
Tyr204), were purchased from Cell Signaling Technol-
ogy (Beverly, MA, USA). Secon dary goat anti-rabbit 
HRP-conjugated antibodies were from Santa Cruz 
Biotechnology (USA). Clarity Western ECL substrate 
(Immunо-Star HRP, BioRad, USA) and medical X-ray 
film (AGFA, Belgium) were used for visualization of im-
munoreactions.
Quantitative RT-PCR. Total RNA was isolated 
from cells using TRI reagent (Sigma-Aldrich, St. 
Louis, MO, USA). Approximately 2 μg of total RNA 
were reverse transcribed with RevertAid Reverse 
Transcriptase, RiboLock RNase Inhibitor (Thermo 
Scientific, USA), and Oligo(dT)23 anchored primer 
(Sigma-Aldrich, St. Louis, MO, USA) according 
to manufacturer’s protocol. cDNA obtained was used 
for real-time PCR. Real-time PCR was performed using 
Maxima SYBR Green/ROX qPCR Master Mix (Thermo 
Scientific, USA) on a sequence detection system 
7500 (Applied Biosystems, Foster City, CA, USA). Sam-
ples were normalized to β2-microglobulin expression. 
Primer design was performed using Primer Design and 
Search Tool (http://bisearch.enzim.hu). The specificity 
of primers was verified using nucleotide-nucleotide 
alignment option (blastn) in BLAST internet program 
(http://www.ncbi.nlm.nih.gov/BLAST/). The pri mers 
for real time PCR are listed in the Table. The PCR cy-
cling conditions were the following: 10 min at 95 °C, 
40 cycles of 15 s at 95 °C and 40 s at 62 °C. Applied 
Biosystems 7500 system software was used for analy-
sis. Ct values were determined for the internal control 
( β2-microglobulin) and the test genes at the same 
threshold level in the exponential phase of the PCR 
curves. Relative quantification (comparative Ct (ddCt) 
method) was used to compare the expression level 
of the test genes with the internal control. Dissociation 
curve analysis was performed after every run to check 
the specificity of the reaction. In all, 3–5 reactions 
(each in triplicates) were run for each gene and a stan-
dard deviation was calculated.
Table. Primers that were used in quantitative RT-PCR
Product Sense primer Antisense primer
IRF4 CCACTACCTCCTTTCCTATC CCGTTCCTTTTCAGAGTCCT
IRF8 CCAACAGATCACCGTCTAA AAGTGCAAAGTAAGGCATC
PU.1 CTTCCAGTTCTCGTCCAA GAGCTTCTTCTTCACCTTC
SPIB GCATACCCCACGGAGAACT GGCTGTCCAACGGTAAGTCT
MITF AGTTGCAACGAGAACAGCAA CGTGGATGGAATAAGGGAAA
BCL6 CTCCGTGCCCATGTGCTTA GAGTCTGAAGGTGCCGGAAA
BLIMP1 GCTTAATACTTGGTGACCTC GTATCTCTTCCTCCCTGGTT
β2-micro-
globulin
CCGTGTGAACCATGTGACTTTGTC TGCGGCATCTTCAAACCTGCATGATC
RESULTS AND DISCUSSION
To clarify the signaling events that may explain 
the functional differences of EBV-transformed 
 B-LCLs from XLP1 patients and conventional B-LCLs, 
we analyzed the kinetics of receptor-mediated Akt 
phosphorylation on S473 and ERK1/2 phosphoryla-
tion on Thr202/Tyr204 that reflect activation of these 
kinases. There kinases were shown to be activated 
via CD150, which interacts with SAP [36], and are 
involved in regulation of cell survival and prolifera-
tion [37, 38]. In these experiments we compared XLP 
B-LCL IARC 739 (interstitial deletion of SH2D1A), with 
conventional B-LCLs T5-1 (SAP negative on protein 
level) and MP-1 (SAP positive on protein level). For 
receptor ligation we used antibodies against CD150, 
CD40 and B-cell receptor (IgM), and also coligation 
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of CD150 with IgM. In these studies on receptor-
mediated Akt and ERK1/2 phosphorylation we would 
like to find answers to following questions: (i) whether 
SAP deficiency affect CD150-mediated signaling, 
(ii) if SAP deficiency influences the kinetics and am-
plitude of Akt and ERK1/2 phosphorylation that is initi-
ated via CD40 and IgM, (iii) whether SAP positive and 
SAP negative  B-LCLs have differences in receptor-
mediated Akt and ERK1/2 activation.
As shown on Fig.1, a, CD150 crosslinking induced 
rapid and sustained Akt phosphorylation in XLP 
 B-LCL IARC 739. Kinetics of Akt phosphorylation 
after CD40 or IgM ligation on these XLP cells was 
similar, however activation amplitude was slightly 
higher, compared with CD150 ligation (Fig. 1, b, c). 
At the same time, kinetics of pAkt after CD150 and 
IgM coligation remained on the level of CD150 alone 
(Fig. 1, d). The peak of Akt phosphorylation was ob-
served at 30 min in all variants of receptor ligation 
(see Fig. 1, a–d).
CD150-mediated ERK1/2 activation, similarly 
to Akt phosphorylation, was not abrogated in XLP 
SAP-deficient B-LCL IARC 739 (Fig. 2, a). pERK1/2 in-
creased at 1 min already, however, the second wave 
of ERK1/2 activation was started at 30 min after re-
ceptor ligation (see Fig. 2, a). Much higher amplitude 
of ERK1/2 phosphorylation started from 1 min was 
detected as a result of CD40 signaling (Fig. 2, b). 
It should be noted that IgM ligation on XLP SAP-
deficient B-LCL IARC 739 mediated very rapid, but 
transient ERK1/2 activation (Fig. 2, c). However, IgM 
and CD150 coligation resulted in rapid intense and 
sustained ERK1/2 phosphorylation (Fig. 2, d).
Comparison of SAP+ and SAP− conventional  B-LCLs 
showed their differences in receptor-initiated Akt 
phosphorylation. First, SAP− cell line T5-1 has elevated 
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Fig. 1. Kinetics of Akt phosphorylation in EBV-transformed XLP B-LCL IARC739 and conventional B-LCLs T5-1 (SAP−) and 
MP-1 (SAP+) in response to CD150 (a), CD40 (b), IgM (c) and CD150 + IgM (d). Western blot analyses of cell lysates. One of four 
representative experiments
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basal levels of both Akt and ERK1/2 phosphoryla-
tion (see Fig. 1, a–d and Fig. 2, a–d). In T5-1 cells 
CD150 ligation induce the most rapid Akt phos-
phorylation (see Fig. 1, a), after IgM crosslinking 
the peak of this enzyme activation was at 15 min 
(see Fig. 1, c), and coligation if these receptors 
did not show sy ne r gistic effect (see Fig. 1, d). 
Receptor-mediated kinetics and amplitude of Akt 
phosphorylation in SAP+ MP-1 cell significantly differ 
from SAP− cells T5-1 (see Fig. 1, a–b). CD40 ligation 
on T5-1 cells resulted in very late Akt phosphoryla-
tion — at 60 min, while in SAP+ cells MP-1 pAkt was 
observed already at 1 min (see Fig. 1, b). On the con-
trary, IgM-induced kinetics and amplitude of Akt 
phosphorylation in MP-1 cells was much lover, than 
in T5-1 cells (see Fig. 1, c). At the same time, coliga-
tion of CD150 with IgM had synergistic effect on Akt 
phosphorylation in SAP+ cells MP-1 (see Fig. 1, d).
Kinetics and amplitude of ERK1/2 phosphorylation 
induced by all variants of receptor ligation was similar 
in both SAP+ and SAP− conventional B-LCLs cell lines 
(see Fig. 2, a–d). It should be noted slight additive ef-
fect of CD150 and IgM coligation (see Fig. 2, d).
Summary for this fragment of studies: 1) SAP defi-
ciency in XLP B-LCL did not abrogate CD150-mediated 
Akt and ERK1/2 phosphorylation; 2) CD150 cross-
linking on XLP B-LCL IARC 739 led to two waves 
of ERK1/2 phosphorylation; 3) IgM ligation on SAP 
deficient XLP B-LCL IARC 739 resulted in short tran-
sient ERK1/2 activation; 4) CD150 signaling in XLP 
B-LCL diminished the amplitude of IgM-mediated 
Akt phosphorylation; 5) SAP+ and SAP− conventional 
B-LCLs have differences in kinetics and amplitude 
of receptor-initiated Akt phosphorylation.
Comparative analysis of receptor-mediated Akt 
and ERK1/2 phosphorylation in XLP and conventional 
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Fig. 2. Kinetics of ERK1/2 phosphorylation in EBV-transformed XLP B-LCL IARC739 and conventional B-LCLs T5-1 (SAP−) and 
MP-1 (SAP+) in response to CD150 (a), CD40 (b), IgM (c) and CD150 + IgM (d). Western blot analyses of cell lysates. One of four 
representative experiments
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B-LCL and functional characteristics of these cell 
lines [34] did not reveal direct correlations. Akt and 
ERK1/2 pathways are the main regulators of cell sur-
vival and proliferation in early B-cell development [37]. 
However, during naïve B cell activation and differentiation 
when the EBV receptor CD21 is expressed, in addition to Akt 
and ERK1/2, other pathways are involved in regulation 
of cell proliferation, especially p38 MAPK [38, 39]. Since sig-
naling pathways create a joint metabolic network, it seems 
unlikely to find a particular and even several pathways that 
are responsible for functional differences between XLP 
and conventional B-LCL. At the same time the divergence 
of XLP and conventional B-LCLs may be stipulated by dis-
turbance of B cell differentiation due to SAP deficiency.
B cell maturation is a process of coordinated tran-
sition of exclusive gene-expression programs that 
is orchestrated by specific transcription factors network. 
To address the question whether SAP deficiency may 
affect the B cell differentiation we studied the limited 
expression profile of transcription factors that play a key 
role in B cell differentiation during the germinal center 
transition and plasma cell development. These include: 
IRF4, IRF8, BCL6, BLIMP1, MITF, PU.1, and SPIB trans-
cription factors.
Interferon regulatory factors 4 and 8 (IRF4 and 
IRF8) are highly homologous to each other and are 
expressed exclusively in cells of the immune sys-
tem [40, 41]. They are characterized by differential 
expression during B cell development that un-
derlies their synergistic or mutual exclusive func-
tioning [40, 41]. It was shown that IRF4 and IRF8 are 
acting synergistically at the small pre-B stage providing 
regulation of rearrangement and transcription of Igκ, 
inhibition of pre-B cell proliferation and promotion 
of pre-B cells migration away from IL-7 enriched bone 
marrow stromal cells [42, 43]. At the same time, du-
ring the antigen-dependent stage of B-cell develop-
ment IRF4 and IRF8 have a differential expression. 
IRF4 is expressed on all stages of B cell maturation 
except the germinal center transition, however its 
expression is upregulated on centrocyte stage during 
exit from the germinal center [40]. It was shown that 
IRF4 plays a critical role in at least three key deve-
lopmental processes: the termination of the germinal 
center B-cell transcriptional program, immunoglobulin 
class switch recombination, and plasma cell deve-
lopment [42]. In contrary, germinal center B cells, par-
ticularly centroblasts, are  cha racterized by the highest 
level of IRF8 expression [40, 41]. IRF8 is the only tran-
scription factor shown to be involved in transcriptional 
induction of a master regulator of germinal center 
reaction BCL6, a transcriptional repressor that is ex-
pressed and acts in mature germinal center B cells 
and also in subpopulation of naïve B lymphocytes [44]. 
BCL6 transcription is directly repressed by IRF4 that 
binds to multiple sites in BCL6 promoter region [44]. 
On the other hand, IRF4 positively regulates expres-
sion of BLIMP1 (B-lympocyte-induced maturation 
protein 1) — another transcription factor that also 
is involved in development and maintaining plasma cell 
phenotype, particularly by repression of BCL6 [42, 45]. 
In turn, BLIMP1 is a positive regulator of IRF4 [45], 
while MITF (microphthalmia-associated transcription 
factor) serves as its negative regulator [46]. MITF 
is essential to maintain naïve B cell program and inhibit 
plasma cell differentiation [46].
EBV transformed B-LCLs are characterized by ele-
vated level of IRF4 expression and signaling via EBV 
latent membrane protein 1 (LMP-1) is responsible 
for IRF4 upregulation [47]. Indeed, in our studies the 
high level of IRF4 expression was detected in con-
ventional B-LCLs T5-1 and MP-1 (Fig. 3, a). However, 
all three tested EBV-transformed XLP B-LCLs had 
significantly lower level of IRF4 expression (see Fig. 
3, a). Since at this stage of differentiation IRF4 and 
IRF8 expression levels are inversed, the high level 
of IRF8 mRNA in XLP B-LCLs could be expected. 
But, in XLP B-LCLs IRF8 expression levels, similarly 
to IRF4, were also significantly lower than in con-
ventional B-LCLs (Fig. 3, b). BCL6 expression level 
in all tested B-LCLs was the lo west between all tested 
transcription factors, moreover, in XLP LCLs it was 
on the border of detection (Fig. 3, c) that correlated 
with the level of IRF8 mRNA (see Fig. 3, b). We did 
not reveal the strong correlation between IRF4 and 
BLIMP1 expression levels, but the lowest levels of both 
transcription factors were found for two XLP B-LCLs 
SC-XLP and  RP-XLP (see Fig. 3, a, d). The expression 
levels of MITF, the negative regulator of IRF4, also did 
not correlate with the IRF4 mRNA levels (Fig. 3, e).
IRF4 and IRF8 by interaction with other transcrip-
tion factors may activate or repress gene expres-
sion. The best-characterized interacting partners 
of IRF4 and IRF8 are the Ets transcription factor 
family members PU.1 and SPIB [40, 42]. They also 
are involved in regulation of B cell viability after BCR 
crosslinking [48]. It should be noted that PU.1 mRNA 
levels were significantly lower in XLP B-LCLs than 
in conventional B-LCLs (Fig. 3, f). Thus, in B-LCLs 
the expression levels of PU.1 (see Fig. 3, f), but not 
SPIB (Fig. 3, g), correlate with IRF4 and IRF8 ex-
pression profile (see Fig. 3, a, b). It should be noted 
that conventional B-LCL MP-1, which express SAP 
on protein level, demonstrated elevated expression 
level of MITF, while SPIB was practically undetectable 
in this cell line (see Fig. 3, e, g). On the other hand, cell 
lines T5-1 (does not express SAP on protein level) and 
XLP B-LCL IARC 739 (also does not express SAP due 
to interstitial deletion of SH2D1A) were characterized 
by the highest level of SPIB expression (see Fig. 3, g).
Taking together, our analysis of transcription 
factors profile in EBV-transformed B-LCLs revealed 
the distinguishing features of XLP B-LCLs with SAP 
deficiency that may affect B cell differentiation. 
We found that significantly reduced IRF4 and PU.1 ex-
pression levels are the key features of XLP B-LCLs. 
In mature B cells CD40 and BCR are involved in up-
regulation of IRF4 expression [40, 42]. So, functional 
impairment of CD40- and BCR-mediated signaling 
in XLP  B-LCLs [34] and diminished expression levels 
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of IRF4 and IRF8, as well as their interacting partner 
PU.1, may be the links in common metabolic chain 
that is crucial for B-cell maturation during germinal 
center transition.
Several lines of evidence are supporting the 
idea that B cells in XLP1 may have an intrinsic de-
fect. First, SAP is expressed in several subsets 
of normal and malignant human and mouse B cells 
and B cell lines [8, 27–33]. Second, B cells from 
SAP-deficient mice have functional impairment 
in vivo and in vitro [30, 49]. Third, XLP1 patients fail 
to produce germinal center derived memory B cells, 
but harbor latent virus in the IgD+IgM+CD27+ sub-
population [17, 19], that may reflect the impairment 
of germinal center maturation due to the functional 
defects in T  and/ or B cells [17]. Fourth, the cell surface 
phenotype and functional features that distinguish 
SAP-deficient XLP B-LCLs from conventional B-LCLs 
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Fig. 3. Analysis of mRNA expression levels of IRF4 (a), IRF8 (b), BCL6 (c), BLIMP1 (d), MITF (e), PU.1 (f), SPIB (g) transcription fac-
tors in XLP B-LCLs (IARC 739, SC-XLP, RP-XLP) in comparison with B-LCLs T5-1 (SAP−), and MP-1 (SAP+). Quantitative real-time 
PCR. Results represented in relative units. Analysis was performed in triplicates, and samples were normalized to β2-microglobulin
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were revealed. The major functional differences con-
cern the modulation of CD95 apoptosis via CD40 and 
CD150 receptors and unresponsiveness to prolifera-
tive signals triggered by CD40 or colligation of BCR 
with CD150 [34]. Fifth, XLP and conventional B-LCL 
have differences in kine tics and amplitude of Akt and 
ERK1/2 phosphorylation. In XLP B-LCL the dominant 
role of CD150 signaling in colligation with IgM should 
be emphasized (see Fig. 1, 2). Sixth, XLP B-LCL had 
a significantly reduced IRF4, IRF8 and PU.1 expression 
levels (see Fig. 3) that imply for impairment of SAP-
deficient B cell differentiation.
When during B cell maturation the lack of SAP 
expression or its mulfunction could affect B cell 
differentiation? It was shown that SAP is a target 
gene of wt p53 [32]. Recently it was found that 
p53 is required for elimination of pre-B cells that failed 
to productively rearrange immunoglobulin VH-DJH 
gene segments [50]. The transcriptional activation 
of p53 is mediated by Bach2, which competes with 
BCL6 for promoter binding, and reverses BCL6-me-
diated repression of p53 [50]. Moreover, BCL6 sup-
presses p53 expression in germinal center B cells [51]. 
However, at this stage of differentiation endogenous 
p53 can be activated by genotoxic agents in Burkitt 
lymphoma and B-LCLs, which induce SAP expression 
via wt p53 [32]. Thus, at least at two stages of B-cell 
maturation the defect in SAP function may affect 
B cell maturation and/or functions. This impairment 
of B cell maturation may underlie the dramatic increase 
of B-cell lymphoma frequency in patients with XLP1.
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